美国代谢功能障碍相关脂肪性肝病临床指南与实际管理之间的差异
该研究基于2022年1月至6月美国85名专科医生和633例患者的横断面调查数据,以2023年美国肝病研究学会(AASLD)实践指南为参照,评估代谢功能障碍相关脂肪性肝炎(MASH)患者的实际管理情况。研究将患者分为目标A组(100例,由初级保健医生/内分泌科医生初诊)和目标B组(533例,由胃肠病学家/肝病学家管理),旨在识别临床实践与指南推荐之间的差距。
要点
- 研究采用横断面调查,回顾性采集2022年1月至6月美国85名医生和633例MASH患者的数据。
- 以2023年AASLD指南为参照,目标A为低患病率人群排除纤维化,目标B为识别/管理高危MASH或肝硬化。
- 目标A组100例由初级保健医生/内分泌科医生初诊,目标B组533例由胃肠病学家/肝病学家管理。
核心结论
- 以2023年AASLD实践指南为参照,当前美国MASH患者的实际管理存在临床实践差距。
研究设计与样本
- 横断面调查,回顾性采集数据,来自美国85名肝病学家、胃肠病学家和内分泌科医生以及633例患者,时间为2022年1月至6月。
主要发现
- 患者分为两组:目标A组100例由初级保健医生/内分泌科医生初诊,目标B组533例由胃肠病学家/肝病学家管理。
关键数值与推荐
- 2023年AASLD实践指南的两个关键目标:目标A为在低患病率人群中排除纤维化,目标B为识别/管理高危MASH或肝硬化。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical practice guidelines can facilitate diagnosis and management of patients with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction associated steatohepatitis (MASH), although their implementation to date has been suboptimal.1,2 Using recently published 2023 American Association for the Study of Liver Diseases (AASLD) practice guidance-based recommendations as a reference,3 we assessed current real-world management of patients with MASH to identify gaps in clinical practice. We extracted data from the Adelphi Real World MASH Disease Specific Programme, a cross-sectional survey with retrospective data capture (from 85 hepatologists, gastroenterologists, and endocrinologists [Supplementary Table 1] and 633 patients [Supplementary Table 2] in the United States between January and June 2022). Two key goals of the AASLD guidance algorithm served as reference points: exclude fibrosis in low-prevalence populations (Goal A) and identify/manage people with 'at-risk' MASH or cirrhosis (Goal B).3 Patients were split into 2 groups: Goal A comprised 100 patients initially diagnosed by primary care physicians (PCPs)/endocrinologists, and Goal B included 533 patients managed by gastroenterologists/hepatologists.
引用
- Rinella ME, Hartman ML, Shinde S, et al. Variance Between Clinical Guidance and Real-World Management of Metabolic Dysfunction-associated Steatotic Liver Disease in the United States. Clin Gastroenterol Hepatol. 2024. PMID: 39209205. doi:10.1016/j.cgh.2024.08.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。